Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Poor Performance Status Clear all
Completed Phase 1 Interventional

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

NCT00986297
View directory record Official record
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

NCT01459497
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation Therapy, Conventional radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
7
States / cities
Austin, Texas • Dallas, Texas • Houston, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

NCT00389584
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Poor Performance Status, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, cognitive assessment, management of therapy complications, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Terminated Phase 1 Interventional

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT00287859
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer

NCT00508144
View directory record Official record
Conditions
Lung Cancer
Interventions
Alimta
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Jul 21, 2026, 6:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiosurgery for Glioblastoma Multiforme

NCT00456612
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CyberKnife
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
66 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01839981
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Jul 21, 2026, 6:43 PM EDT
Completed No phase listed Observational

Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status

NCT05634551
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Questionnaires, Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 21, 2026, 6:43 PM EDT
Terminated Phase 4 Interventional Results available

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions
Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

NCT00193323
View directory record Official record
Conditions
Lung Cancer
Interventions
Docetaxel, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2010 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, radiation therapy
Biological · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Trial of Poor Performance Status Patients (ToPPS)

NCT00892710
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Stereotactic Radiation Therapy in Treating Patients With Brain Metastases

NCT00006259
View directory record Official record
Conditions
Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 21, 2026, 6:43 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab for Advanced NSCLC and PS 2-3

NCT05589818
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nighttime Feeding and Morning Endurance Performance

NCT02160873
View directory record Official record
Conditions
Poor Performance Status
Interventions
chocolate milk, flavor-matched placebo
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 21, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

NCT01474551
View directory record Official record
Conditions
Melanoma
Interventions
vemurafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

NCT00193479
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

NCT00891878
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions
capecitabine, sunitinib malate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
182
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jul 21, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885
View directory record Official record
Conditions
Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions
infliximab, docetaxel, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
188
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 21, 2026, 6:43 PM EDT